中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

限定条件        
已选(0)清除 条数/页：   排序方式：
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping;  Hu, Chen;  Wang, Wenliang;  Wu, Hong;  Huang, Tao;  Zhao, Ming;  Wang, Wenchao;  Hu, Zhenquan;  Liu, Qingwang;  Wang, Beilei;  Wang, Li;  Li, Lili;  Ge, Jian;  Ren, Tao;  Xia, Ruixiang;  Liu, Jing
收藏  |  浏览/下载：52/0  |  提交时间：2019/11/27
BCR-ABL  PDGFR  chronic myeloid leukemia  kinase inhibitor  
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino) cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl) tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 158, 页码: 896-916
作者:  Wang, Beilei;  Wu, Jiaxin;  Wu, Yun;  Chen, Cheng;  Zou, Fengming;  Wang, Aoli;  Wu, Hong;  Hu, Zhenquan;  Jiang, Zongru;  Liu, Qingwang;  Wang, Wei;  Zhang, Yicong;  Liu, Feiyang;  Zhao, Ming;  Hu, Jie;  Huang, Tao;  Ge, Juan;  Wang, Li;  Ren, Tao;  Wang, Yuxin;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：25/0  |  提交时间：2019/12/25
CDK9  Kinase inhibitor  Structure-activity relationship  Leukemia